A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of Administering ALECSAT to Pancreas Cancer Patients

Trial Profile

A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of Administering ALECSAT to Pancreas Cancer Patients

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Cancer vaccine-ALECSAT (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors CytoVac
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 12 Aug 2015 Planned End Date changed from 1 Mar 2015 to 1 Sep 2015, according to ClinicalTrials.gov
    • 22 Apr 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top